Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPF neoadjuvant chemotherapy followed by cisplatin chemoradiation for hypopharyngeal cancer
ACTRN12610000870055Phase 2Active, not recruiting
- Sponsor
- Shiraz University of Medical Sciences
- Start
- May 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in hypopharyngeal cancer and squamous cell carcinoma of the hypopharynx, sponsored by Shiraz University of Medical Sciences. Primary endpoint: Clinical response rate. Started May 2011; status: active, not recruiting.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
hypopharyngeal cancersquamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on ACTRN12610000870055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000870055.